Pharmacogenomics of Interferon-Induced Depression
干扰素引起的抑郁症的药物基因组学
基本信息
- 批准号:7418658
- 负责人:
- 金额:$ 17.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-06-01 至 2010-05-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAncillary StudyBeck depression inventoryBiological AssayCandidate Disease GeneClassClinical PharmacologyComputer softwareConsultationsDNADataDevelopmentDrug KineticsEquipment and supply inventoriesExposure toFutureGenesGeneticGenetic PolymorphismGenetic Predisposition to DiseaseGenomeGoalsHepatitis CHumanHuman GeneticsIndividualInterferon-alphaInterferonsIntronsLaboratoriesMental DepressionMental HealthMicro Array DataModelingMusPatientsPharmacogeneticsPharmacogenomicsPilot ProjectsProtocols documentationPsychiatristQuantitative GeneticsReadingRecording of previous eventsResearchResearch DesignResearch TrainingRoleScoreTechniquesTrainingTreatment/Psychosocial EffectsTryptophan 5-monooxygenasecohortdepressive symptomsdesigngenetic associationprogramspromoterprospectivepsychosocialresponseserotonin transporter
项目摘要
DESCRIPTION (provided by applicant): The candidate for this K23 application is a psychiatrist who proposes to acquire expertise in pharmacogenomics. He intends to accomplish this goal through guided didactics and consultations and a research protocol designed to examine genetic polymorphisms that may affect vulnerability to interferon-alpha-induced depression (I-ID) in humans. Interferon-alpha can trigger depression in about 25% of patients and is the primary treatment for hepatitis C, which affects about 4 million individuals in the U.S. In addition to this being a significant mental health issue in its own right, I-ID offers the opportunity to feasibly examine a prospective human model of depression. Therefore, specific candidate polymorphisms will be examined in a well-characterized cohort of patients with hepatitis C who are assessed prior to interferon-a treatment and who are currently euthymic. The development of depression will be prospectively followed, along with pharmacokinetic assessments of interferon-a exposure. In conjunction with didactic training, this research will provide a platform for acquiring expertise in quantitative genetics and associational analyses in clinical pharmacology research, and designs using high throughput genetic polymorphism assays. The didactic training will involve specific classes in human genetics, supervised readings and software tutorials, and exposure to high throughput laboratory techniques. A small ancillary pilot study will also be included to ascertain, in parallel, potential candidate genes for further genetic association analyses of I-ID. This ancillary study will generate pilot micro-array data in an analogous murine model of interferon-alpha exposure, ascertaining the genome-wide set of frontal cortical genes affected by interferon-alpha. In conjunction with didactic training in the analysis and collaborative verification of micro-array data, this ancillary project will provide a training platform for incorporating the use of micro-arrays into psychiatric pharmacogenetic research. This developmental program will initiate the candidate's long-term interdisciplinary and integrative strategy for delineating genetic vulnerability to depression.
描述(由申请人提供):这份K23申请的候选人是一名精神病学家,他建议获得药物基因组学方面的专业知识。他打算通过指导教学和咨询以及一项研究方案来实现这一目标,该方案旨在检查可能影响人类对干扰素-α诱导的抑郁症(I-ID)易感性的基因多态。干扰素-α可以在大约25%的患者中引发抑郁症,是丙型肝炎的主要治疗方法,丙型肝炎在美国影响着大约400万人。除了这本身就是一个重大的精神健康问题外,i-ID还提供了可行的机会来研究抑郁症的预期人类模型。因此,将在丙型肝炎患者队列中检查特定的候选基因多态性,这些患者在接受干扰素-a治疗前进行了评估,目前正处于良好状态。将前瞻性地跟踪抑郁症的发展,以及干扰素-a暴露的药代动力学评估。结合教学培训,这项研究将提供一个在临床药理学研究中获得数量遗传学和关联分析专业知识的平台,并使用高通量遗传多态分析进行设计。教学培训将包括人类遗传学的特定课程、监督阅读和软件教程,以及接触高通量的实验室技术。同时,还将包括一项小型辅助试点研究,以确定潜在的候选基因,以便进一步进行I-ID的遗传关联分析。这项辅助研究将在干扰素-α暴露的类似小鼠模型中产生试点微阵列数据,确定受干扰素-α影响的全基因组额叶皮质基因集。结合微阵列数据分析和协作验证的教学培训,这一辅助项目将为将微阵列的使用纳入精神科药物遗传学研究提供一个培训平台。这一发展计划将启动候选人的长期跨学科和综合战略,以描绘抑郁症的遗传易感性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FRANCIS E LOTRICH其他文献
FRANCIS E LOTRICH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FRANCIS E LOTRICH', 18)}}的其他基金
Transcriptome association with inflammation-related major depression
转录组与炎症相关重度抑郁症的关联
- 批准号:
8511838 - 财政年份:2012
- 资助金额:
$ 17.36万 - 项目类别:
Transcriptome association with inflammation-related major depression
转录组与炎症相关重度抑郁症的关联
- 批准号:
8384387 - 财政年份:2012
- 资助金额:
$ 17.36万 - 项目类别:
Vulnerability to major depression: The role of delta sleep in patients receiving
易患重度抑郁症:德尔塔睡眠对接受治疗的患者的作用
- 批准号:
8106346 - 财政年份:2010
- 资助金额:
$ 17.36万 - 项目类别:
Vulnerability to major depression: The role of delta sleep in patients receiving
易患重度抑郁症:德尔塔睡眠对接受治疗的患者的作用
- 批准号:
7992163 - 财政年份:2010
- 资助金额:
$ 17.36万 - 项目类别:
Vulnerability to major depression: The role of delta sleep in patients receiving
易患重度抑郁症:德尔塔睡眠对接受治疗的患者的作用
- 批准号:
8240527 - 财政年份:2010
- 资助金额:
$ 17.36万 - 项目类别:
Vulnerability to Major Depression and the Role of Sleep with Interferon-Alpha
易患重度抑郁症以及睡眠与干扰素-α 的作用
- 批准号:
8606776 - 财政年份:2010
- 资助金额:
$ 17.36万 - 项目类别:
Vulnerability to Major Depression and the Role of Sleep with Interferon-Alpha
易患重度抑郁症以及睡眠与干扰素-α 的作用
- 批准号:
8414844 - 财政年份:2010
- 资助金额:
$ 17.36万 - 项目类别:
Pharmacogenomics of Interferon-Induced Depression
干扰素引起的抑郁症的药物基因组学
- 批准号:
6913106 - 财政年份:2005
- 资助金额:
$ 17.36万 - 项目类别:
Pharmacogenomics of Interferon-Induced Depression
干扰素引起的抑郁症的药物基因组学
- 批准号:
7059853 - 财政年份:2005
- 资助金额:
$ 17.36万 - 项目类别:
Pharmacogenomics of Interferon-Induced Depression
干扰素引起的抑郁症的药物基因组学
- 批准号:
7618648 - 财政年份:2005
- 资助金额:
$ 17.36万 - 项目类别:
相似海外基金
Coronary Artery Calcium in the PRagmatic EValuation of evENTs And Benefits of Lipid lowering in the Elderly: CAC PREVENTABLE Ancillary Study
冠状动脉钙对老年人降脂事件和益处的实用评估:CAC 可预防的辅助研究
- 批准号:
10674482 - 财政年份:2021
- 资助金额:
$ 17.36万 - 项目类别:
A Longitudinal Study of Periodontal Infections and Alzheimer's Disease: The WHICAP Ancillary Study of Oral Health
牙周感染和阿尔茨海默病的纵向研究:口腔健康的 WHICAP 辅助研究
- 批准号:
10381292 - 财政年份:2021
- 资助金额:
$ 17.36万 - 项目类别:
The PREVENTABLE Physical Performance Ancillary Study
可预防的身体表现辅助研究
- 批准号:
10366941 - 财政年份:2021
- 资助金额:
$ 17.36万 - 项目类别:
The PREVENTABLE Physical Performance Ancillary Study
可预防的身体表现辅助研究
- 批准号:
10495229 - 财政年份:2021
- 资助金额:
$ 17.36万 - 项目类别:
StAtins Use in intRacereberal hemorrhage patieNts MRI (SATURN MRI) Ancillary Study
他汀类药物在脑出血患者中的使用 MRI (SATURN MRI) 辅助研究
- 批准号:
10179775 - 财政年份:2021
- 资助金额:
$ 17.36万 - 项目类别:
Mechanistic Ancillary Study to the Natural History Study of ADO2 to Determine Clinical Severity
ADO2 自然史研究的机制辅助研究以确定临床严重程度
- 批准号:
10375070 - 财政年份:2021
- 资助金额:
$ 17.36万 - 项目类别:
A Longitudinal Study of Periodontal Infections and Alzheimer's Disease: The WHICAP Ancillary Study of Oral Health
牙周感染和阿尔茨海默病的纵向研究:口腔健康的 WHICAP 辅助研究
- 批准号:
10631203 - 财政年份:2021
- 资助金额:
$ 17.36万 - 项目类别:
Coronary Artery Calcium in the PRagmatic EValuation of evENTs And Benefits of Lipid lowering in the Elderly: CAC PREVENTABLE Ancillary Study
冠状动脉钙对老年人降脂事件和益处的实用评估:CAC 可预防的辅助研究
- 批准号:
10296788 - 财政年份:2021
- 资助金额:
$ 17.36万 - 项目类别:
COCOA PAD II Trial: Microbiome Ancillary Study
COCOA PAD II 试验:微生物组辅助研究
- 批准号:
10610072 - 财政年份:2021
- 资助金额:
$ 17.36万 - 项目类别:
An MRI Ancillary Study of Malaria Fever Control RCT
疟疾发热控制的 MRI 辅助随机对照试验
- 批准号:
10343754 - 财政年份:2020
- 资助金额:
$ 17.36万 - 项目类别:














{{item.name}}会员




